C-CAR168

N/A

Report date: 2025/06/18 16:36:16

Base Information

Drug NameC-CAR168
Drug Alias NameC-CAR168
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsB-lymphocyte antigen CD20 modulatorsT lymphocyte replacements
TargetsB-cell maturation proteinB-lymphocyte antigen CD20
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAbelZeta IncAbelZeta Pharma IncCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A